Non-immunoglobulin scaffolds: a focus on their targets

被引:145
作者
Skrlec, Katja [1 ]
Strukelj, Borut [1 ,2 ]
Berlec, Ales [1 ]
机构
[1] Jozef Stefan Inst, Dept Biotechnol, Ljubljana 1000, Slovenia
[2] Univ Ljubljana, Fac Pharm, Ljubljana 1000, Slovenia
关键词
non-immunoglobulin scaffolds; antibody alternatives; binders; ANKYRIN REPEAT PROTEIN; REAGENTLESS FLUORESCENT BIOSENSORS; GROWTH-FACTOR RECEPTOR; KNOWLEDGE-BASED DESIGN; HIGH-AFFINITY; BINDING-PROTEINS; AFFIBODY MOLECULES; ENGINEERED PROTEINS; LACTOCOCCUS-LACTIS; STRUCTURAL BASIS;
D O I
10.1016/j.tibtech.2015.03.012
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Non-immunoglobulin (non-Ig) scaffolds are, in contrast to antibodies, small single-domain proteins that require no post-translational modification, often lack disulfide bonds, and can undergo straightforward multimerization. Among the 20 different types of non-Ig scaffolds, Adhirons, Alphabodies, Centyrins, Pronectins, Repebodies, Affimers, and Obodies have been introduced in the past 4 years. 102 proteins have been specifically targeted by 139 different non-Ig scaffold binders. The most frequent application of non-Ig scaffolds is in the treatment and diagnosis of cancer and inflammatory diseases, and 10 non-Ig scaffolds have already been tested in clinical trials. Recently, non-Ig scaffolds have often been used in research as structure determination chaperones, for intracellular monitoring of post-translational modifications, and as antibody alternatives for microscopy, flow cytometry, and Western blotting.
引用
收藏
页码:408 / 418
页数:11
相关论文
共 103 条
[1]   Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes [J].
Allen, Joshua E. ;
Ferrini, Roger ;
Dicker, David T. ;
Batzer, Glenda ;
Chen, Elise ;
Oltean, Daniela I. ;
Lin, Bing ;
Renshaw, Mark W. ;
Kretz-Rommel, Anke ;
El-Deiry, Wafik S. .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (10) :2087-2095
[2]   Replacing Antibodies: Engineering New Binding Proteins [J].
Banta, Scott ;
Dooley, Kevin ;
Shur, Oren .
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 15, 2013, 15 :93-113
[3]   Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules [J].
Baum, Richard P. ;
Prasad, Vikas ;
Mueller, Dirk ;
Schuchardt, Christiane ;
Orlova, Anna ;
Wennborg, Anders ;
Tolmachev, Vladimir ;
Feldwisch, Joachim .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (06) :892-897
[4]   Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab [J].
Benson, Jacqueline M. ;
Sachs, Clifford W. ;
Treacy, George ;
Zhou, Honghui ;
Pendley, Charles E. ;
Brodmerkel, Carrie M. ;
Shankar, Gopi ;
Mascelli, Mary A. .
NATURE BIOTECHNOLOGY, 2011, 29 (07) :615-624
[5]  
Binder U., 2012, THERAPEUTIC PROTEINS, V1st, P63, DOI [DOI 10.1002/9783527644827.CH4, 10.1002/9783527644827.ch4]
[6]   High-affinity binders selected from designed ankyrin repeat protein libraries [J].
Binz, HK ;
Amstutz, P ;
Kohl, A ;
Stumpp, MT ;
Briand, C ;
Forrer, P ;
Grütter, MG ;
Plückthun, A .
NATURE BIOTECHNOLOGY, 2004, 22 (05) :575-582
[7]   Engineering novel binding proteins from nonimmunoglobulin domains [J].
Binz, HK ;
Amstutz, P ;
Plückthun, A .
NATURE BIOTECHNOLOGY, 2005, 23 (10) :1257-1268
[8]   A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action [J].
Brack, Simon ;
Attinger-Toller, Isabella ;
Schade, Babette ;
Mourlane, Frederic ;
Klupsch, Kristina ;
Woods, Richard ;
Hachemi, Helen ;
von der Bey, Ulrike ;
Koenig-Friedrich, Susann ;
Bertschinger, Julian ;
Grabulovski, Dragan .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (08) :2030-2039
[9]   Knowledge-based design of reagentless fluorescent biosensors from a designed ankyrin repeat protein [J].
Brient-Litzler, Elodie ;
Plueckthun, Andreas ;
Bedouelle, Hugues .
PROTEIN ENGINEERING DESIGN & SELECTION, 2010, 23 (04) :229-241
[10]   New concepts and aids to facilitate crystallization [J].
Bukowska, Magdalena A. ;
Gruetter, Markus G. .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2013, 23 (03) :409-416